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Clinical Evaluation of Liver Structure and
Function in Humans Exposed to
Halogenated Hydrocarbons
by Philip S. Guzelian*
An unresolved question is whether humans exposed to comparatively low doses of persistent environ-
mental chemicals such as polyhalogenated biphenyls or organochlorine pesticides are at risk for injury
to the liver. Cross-sectional epidemiologic studies suggest that these chemicals may produce statistically
significant but clinically mild abnormalities in the commonly employed chemical tests of liver function.
The few reports of human liver morphology reveal nonspecific changes reflecting effects of lipophilic
chemicals. There is evidence that chemicals ofthis category in at least some doses cause induction ofliver
microsomal enzymes involved in biotransformation of foreign substances. This finding has been docu-
mented by measurements of the clearance of model drugs or the appearance in the urine of steroid
metabolites or glucaric acid. Although a positive statistical correlation between the concentrations of
these chemicals in serum and the serum y-glutamyltranspeptidase activity has been reported, the non-
specificity of the latter enzyme precludes conclusion that this change is indicative of induction of liver
microsomal enzymes. Although the effects of this type of environmental chemical are not indicative of
progressive liver disease, only prospective clinical trials can resolve the issue of the risk for future de-
velopment of liver malignancy.
The liver plays a complex role in the interaction be-
tween man and his chemical environment. The liver
serves as the major site for biotransformation and met-
abolic elimination of many foreign substances, but may
also serve as a target organ for the toxicity of meta-
bolically activated environmental agents. High doses of
polychlorinated biphenyls (PCBs) orotherlipophilic hal-
ogenated hydrocarbons in animals exert profound he-
patoxic manifestations including liver cell necrosis,
cholestasis, or in long-term exposure, malignancy.
However, except for rare instances of overt poisoning
ofhumans with these chemicals (1), the hepatic effects
in man of exposure to halogenated hydrocarbons through
environmental contact are generally inconspicuous (2).
Exposure to small amounts ofPCBs and other chem-
icals in the environment produces subtle changes in
standard clinical tests ofliver function. Therefore most
ofthe available information has, by necessity, come from
cross-sectional epidemiologic studies examining pri-
marily groups ofpeople exposed to these chemicals be-
cause oftheir occupation. For example, several studies
(3-6) of groups of electrical workers whose average
serum or blood concentrations ofPCBs were in the range
of 33.4 to 524 ng/mL revealed statistically significant
changes inlivertests, summarized in Table 1. However,
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the findings were not entirely uniform among these
studies. A significant number of patients had liver en-
largement on physicalexamination. The serumbilirubin
tended to be in the lower range ofnormal whereas serum
transaminase activity tended to be in the high normal
range or slightly elevated. The serum y-glutamyltran-
speptase activity (y-GTP) was positively correlated with
the serum level of PCBs. The latter result was also
reported inpeople exposed to sludge contaminated with
PCBs (7) and in residents of Triana (8). The lack of
consistency in demonstrating effects of PCBs on com-
mon liver tests is also reflected in new studies reported
inthisvolume. Thereis one reportthatPCBs may cause
induction ofthe liver microsomal drug-metabolizing en-
zyme systems in man (9) as is the case for experimental




Agent Hepatomegaly BR AST/ALTy-GTPinduction Reference
PCB + T + (4-9)
Yusho + I/ i - NRa NRa (10-12)
PBB NRa T + (14,15)
DDT NRa - 1a + (16-18)
P-HCH + - - - + (19)
Chlordecone + - - - + (20,21)
aNR = not reported.P. S. GUZELIAN
animals. Yusho refers to the outbreak of poisonings in
Japan in people who consumed rice oil that contained
PCBs (10) plus polychlorinated dibenzofurans and diox-
ins. Initially, many of the patients presented with he-
patomegaly and in one series 11% were said to show
jaundice (12).
A more recent study, seven years afterthe outbreak,
however, showed that there was a statistically signifi-
cant reduction in serum bilirubin that correlated in-
versely with residual serum levels of poorly excreted
PCB isomers (13). Transaminase levels were said to be
normal. Studies of two large cohorts exposed to poly-
brominated biphenyls (PBBs) revealed no significant
change inbilirubin, slight elevation intransaminase and
in -y-GTP, and an elevation in urinary porphyrins that
positively correlated with serum levels of the PBBs
(14,15). Cross-sectional studies ofgroups with different
serum DDT levels revealed hypobilirubinemia but no
consistent relationship with transaminase (16). A pos-
itive correlation was found between the -y-GTP and the
levels of serum DDT and its isomers in residents of
Triana, AL (17). Evidence for induction of liver drug-
metabolizing enzymes was found in one study of DDT
workers (18).
,B-Hexachlorocyclohexane (,B-HCH, a component of
lindane) is an insecticide ingredient that, like PCBs, is
highly lipophilic and is slowly excreted from the body.
In studies of workers occupationally exposed to HCH
for up to 18 years there was still evidence ofinduction
ofliver enzymes 7 years after the last exposure. How-
ever, physical examination, the standard liver chemis-
try tests and rates of elimination of indocyanine green
and galactose all were normal (19). Among the most
complete data for an environmental agent of this class
are the results ofstudies of32 workers exposed to high
concentrations of the insecticide chlordecone, known
more commonly as Kepone. Despite the fact that these
workers had high concentrations ofchlordecone in their
serum, adipose tissue, and liver (20), standard chemical
tests were in each case repeatedly negative (21). How-
ever, there was liver enlargement and tests for liver






Increased cytoplasmic (lipofuscin) 11
Fatty infiltration 3
Portal inflammatory cells (mild) 5
Portal fibrosis (mild) 3
Focal areas of proliferated reticuloendothelial cells 3
Electron microscopy
Proliferated smooth endoplasmic reticulum 11
Dilated, vesiculated, rough endoplasmic reticulum 6
Lipid vacuoles 8
Branchedmitochondriawithparacrystallineinclusions 4
Blebs in hepatocyte sinusoidal membrane 4
aReprinted by permission (21).
microsomal enzyme induction were positive. Clearance
ofsulfobromophthalein (BSP) was normal in all ofthese
patients. To summarize from the available data, one
may conclude that the amounts of chlorinated hydro-
carbons commonly found in humans are associated with
changes in liver tests that are statistically significant
and yet subtle and, thus, not readily recognized in the
ordinary clinical setting.
Despite the large numbers ofpeople exposed to these
chemicals there is surprisingly little information on hu-
man liver histopathology. The most complete informa-
tion comes from 12 needle biopsy specimens from
workers exposed to chlordecone (Table 2). Light mi-
croscopic examination revealed minimal steatosis, focal
proliferation ofreticuloendothelial cells and hypogly co-
genation of nuclei. Two liver biopsies of patients ex-
posed to PBBs (unknown levels) revealed only mild
infiltration of both large and small fat droplets (22).
Electron microscopic examination of liver specimens
from patients exposed to chlordecone showed prolifer-
ation of the endoplasmic reticulum. There were also
numerous residual bodies, branched mitochondria with
paracrystallineinclusions, andblebsintheplasmamem-
brane. The mitochondrial changes are nonspecific and
have been noted in a wide variety of pathologic condi-
tions of the liver. A report of one human liver biopsy
in a patient exposed to PCBs alsorevealed proliferation
of the smooth endoplasmic reticulum, increased num-
bers of residual bodies and nonspecific mitochondrial
abnormalities (23). Perhaps the reason that there is so
little human liver biopsy material available is that phy-
sicians believe liver biopsy is unwarranted in cases of
exposure to PCBs orotherrelated chemicals when liver
tests are at most only minimally abnormal. This is un-
fortunate, because liver biopsy performed by an expe-
rienced hepatologist carries little risk and in the case
of the chlordecone workers provided essential infor-
mation for diagnosis and management and, ultimately,
for designing a rational approach to treatment (20,21).
A prominent effect of lipophilic halogenated hydro-
carbon chemicals both in animals and, apparently, in
manis toinducetheenzymes inthe smoothendoplasmic
reticulum responsible for xenobiotic biotransformation.
This has generally been regarded as an adaptive re-
sponse of the liver rather than as a manifestation of
hepatotoxicity per se. However, induction of liver mi-
crosomal enzymes may alter the rate or pathways of
metabolism of other xenobiotic or endogenous sub-
strates. Many compounds that induce drug-metaboliz-
ing enzymes also are classified as tumor promotors in
experimental carcinogenesis systems. Hence, it would
be desirable to have simple, specific, and clinically prac-
ticalteststhatwouldrecognize livermicrosomalenzyme
induction in man. One approach is measurement ofthe
clearance of model drugs that rely on liver metabolism
for their elimination. Clearance can be assessed from
the rate of disappearance from plasma (for example,
antipyrine or tolbutamide) or from the rate of appear-
ance in the breath of metabolites derived from radio-
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Table 3. Effect of lipophilic chlorinated hydrocarbons on
clearance of antipyrine in humans.
Antipyrine half-life (n)
Agent Control Exposed Reference
PCB 15.6 (5) 10.8 (5) (9)
DDT (and others) 13.1 (33) 7.7 (26) (27)
Lindane 12.9 (3) 11.7 (9) (28)
1-HCH 14.7 (4) 7.4 (6) (19)
Chlordecone 14.8 (3) 7.5 (10) (21)
actively labeled drug substrates (for example,
aminopyrine, caffeine or diazepam). Accelerated me-
tabolism of these drugs in induced subjects is presum-
ably due to accumulation in the microsomes of the
cytochromes P-450, a group ofhemoproteins capable of
binding drugs and catalyzing the oxidative metabolism
of many foreign and endogenous compounds. Indeed,
urinary excretion of steroid metabolites may serve as
a reflection ofthe cytochrome P-450-mediated drug-ox-
idizing activity since steroids also serve as substrates
for these versatile hemoproteins. Many of the com-
pounds that induce the cytochromes P-450 in the liver
also induce microsomal enzymes involved in the metab-
olism of glucuronic acid (26). Therefore, increased uri-
nary excretion ofglucaric acid, a breakdown product of
glucuronic acid, may signify proliferation ofthe smooth
endoplasmic reticulum in the liver (25). It has been pro-
posed that y-GTP activity in the serum may also reflect
microsomal enzyme induction in the liver (26).
It is surprising that the repetitively published gen-
eralitiesaboutthe effects ofPCBsandrelatedchemicals
on human liver microsomal enzymes have been derived
from surprisingly few studies (Table 3). A significant
reduction in the half-life of antipyrine disappearance
from plasma was seen with groups exposed to PCBs
(9), to a mixture ofchlorinated hydrocarbons (primarily
DDTbutalsoincludingchlordane and lindane), to askin
cream containing lindane (28) and to ,-HCH (19). Ac-
celerated clearance ofantipyrine from saliva was found
in persons exposed to pesticides (29). Unfortunately,
none of these studies compared the concentrations of
the inducing agent in plasma orliver to the rate ofdrug
metabolism so that the concentration these environ-
mental agents required to achieve a threshold ofinduc-
tion in human liver is uncertain. However, it has been
established that antipyrine half-life was shortened in
chlordecone-poisoned workers (Table 3) at a time when
the concentration ofthis pesticide in the plasma was no
less than 1,000 ng/mL. Workers exposed to DDT ex-
hibited urinary excretion of6,-hydroxycorticosterol with
apossible threshold forthis effectbeingassociated with
a serum concentration ofDDT of300 to 500 ng/mL (18).
Excretion ofurinary glucaric acid has received little
attention as a way to test for microsomal enzyme in-
duction in the liver by environmental chemicals. One
study of workers exposed to DDT failed to reveal ele-
vated excretion ofurinary glucaric acid (30). However,
thehighest serum DDT concentration inthisgroup (167
































FIGURE 1. Urinary excretion ofglucaric acid in workers exposed to
chlordecone. At the time ofinitial evaluation (1976) and following
cessation of cholestyramine therapy (1978), urine was obtained
from workers exposed to chlordecone, and glucaric acid concen-
trationwas measured asdescribedinthemanuscript. The average
values (nmole D-glucaro-1,4-lactone/g creatinine, mean ± SD) were
(@) for the workers, 51.3 ± 16.5 in 1976 and 5.0 ± 2.4 in 1978;
(0) for normal controls, 8.7 ± 5.3 in 1976 and 5.6 ± 2.2 in 1978;
(A) for patients receiving drugs, 50.1 ± 25.0.
with liver enzyme induction in another group of DDT
workers based on the measurements ofdrug clearance
or excretion of steroid metabolites (18). Hence, it re-
mains uncertain whether DDT (even in higher doses)
affects urinary excretion of glucaric acid at all. Defini-
tive evidence that an organochlorine chemical can in-
crease urinary excretion of glucaric acid comes from




of epilepsy. Moreover, after all the patients had been
placed on cholestyramine, an orally administered an-
ionic binding resin that stimulates the elimination of
chlordeconefromthebody(20), thelevelsofchlordecone
in the plasma fell to low or undetectable levels and the
excretion ofglucaric acidfellbackintothe normalrange
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in each case. Fromthese results we have estimated that
the serum level of chlordecone associated with enzyme
induction in the liver is in the range of 100 to 500 ng/
mL.
Epidemiologists have come to rely on the y-GTP as
a marker for induction ofliver microsomal enzymes be-
cause the test is inexpensive and simple to perform.
However, limitations in the significance of the y-GTP
must be fully appreciated. There is now extensive data
regarding the localization of y-GTP in human tissue.
Theenzymeisnotfoundintheliverexclusively. Rather,
y-GTP is present in almost every tissue of the body
(bone being a notable exception) with significant amounts
in kidney, pancreas, spleen and intestine (31). A second
important point is that y-GTP is not a microsomal en-
zyme. In normal human liver (32) and in animal liver
(33,34), y-GTP has been localized to the hepatocyte
plasma membrane. It is also found in the apical portions
of some human bile duct cells (32). Unresolved is the
question of whether small amounts of this enzyme are
found also in nonparenchymal liver cells (35). Under
some liver pathologic conditions in humans, y-GTP ac-
tivity is intensified in the area of the bile cannaliculus
and this could account forincreased activity inthe serum.
Even this point is uncertain, however, because despite
elevated y-GTP activity in the serum of patients with
many types ofliver disease, the overall activity ofthis
enzyme in liver tissue was not necessarily increased
(36).
Initial enthusiasm for the y-GTP test may be subsid-
ing because of the realization that y-GTP (36) activity
inhuman serumisincreased in association with somany
physiologic conditions. It is true that patients receiving
somedrugs, particularlyantiepileptic drugssuch asbar-
bituates and phenytoin, have significantly increased -y-
GTP activity (26,27). However, the enzyme is increased
in almost every form of hepatobiliary disease (36,38-
41) and because the test is among the most sensitive,
it will be elevated in subtle forms of liver injury such
as resolution of asymptomatic viral hepatitis (42). y-
GTP is also elevated in diabetes or other pancreatic
diseases (31,43), inkidney diseases (44) and, forreasons
that are unclear, with congestive heart failure (45), an-
gina (46) myocardial infarction (47) and many other con-
ditions (48), even though there may be no apparent
effectofthese diseases onthe liver. Amosttroublesome
confounding factor that may complicate the usefulness
of y-GTP in epidemiologic studies is that consumption
of alcohol even in moderate amounts may elevate the
y-GTP activity in as many as 70% ofthe subjects (49-
54). Another confounding factor is that the test is ele-
vated in babies and also appears to be higher in adult
males than in females (55). Indeed, birth control pills
appear to decrease y-GTP at least under conditions
where the enzyme is elevated in viral hepatitis (56).
In addition to "false positive" results forliverenzyme
induction the y-GTP can give "false negative" results
as well. For example, administration of rifampicin to
normal subjects increased clearance ofhexobarbital and
urinary glucaric acid, and yet -y-GTP activity remained
normal (57). In at least one patient given dichlor phen-
azone, warfarin clearance was accelerated whereas -y-
GTP activity remained unchanged (26), although dich-
lorophenazone did increase -y-GTPin mostsubjects (26).
Finally, despite the strong evidence for induction of
liver microsomal enzymes in chlordecone-poisoned
workers, y-GTP activity remained normal (21). Thus an
elevated y-GTP activity, particularly as taken out of
clinical context in an epidemiologic study, need not in-
dicate liver involvement, whatsoever, let alone induc-
tion of drug-metabolizing enzymes in the liver. Hence,
while reported associations between y-GTP activity
serumlevelsofPCBsorofDDTstand asvalidstatistical
associations conclusions that the elevation of-y-GTP ac-
tivity represents liver microsomal enzyme induction
must be regarded as tentative pending further
substantiation.
In summary, environmental agents produce subtle
yet statistically demonstrable changes in human liver
at least asjudged by routine chemistry evaluation. Un-
for tunately, insufficient data is available relating liver
concentrations ofthese chlorinated compounds and de-
tectable changes in liver tests to be able to establish
with confidence threshold levels for observable effects.
Thereisnoevidence thatthese subtle changes arelikely
to lead to clinically significant liver disease. However,
because these chemicals produce liver malignancies in
experimental animals there will continue to be concern
about human liver cancer until appropriate epidemio-
logic studies are carried out.
Dr. Guzelian is the recipient of a Research Career Development
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